CytomX Therapeutics, Inc. (CTMX)
CTMX Stock Price Chart
Explore CytomX Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CTMX price movements and trends.
CTMX Company Profile
Discover essential business fundamentals and corporate details for CytomX Therapeutics, Inc. (CTMX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Oct 2015
Employees
119.00
Website
https://www.cytomx.comCEO
Sean A. McCarthy DPHIL
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
CTMX Financial Timeline
Browse a chronological timeline of CytomX Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.04, while revenue estimate is $11.92M.
Earnings released on 7 Aug 2025
EPS came in at -$0.00 surpassing the estimated -$0.06 by +98.02%, while revenue for the quarter reached $18.66M , beating expectations by +2.07%.
Earnings released on 12 May 2025
EPS came in at $0.27 surpassing the estimated $0.18 by +50.00%, while revenue for the quarter reached $50.92M , beating expectations by +1.17K%.
Earnings released on 6 Mar 2025
EPS came in at $0.22 surpassing the estimated -$0.23 by +195.65%, while revenue for the quarter reached $38.09M , beating expectations by +192.12%.
Earnings released on 7 Nov 2024
EPS came in at $0.07 surpassing the estimated -$0.17 by +141.18%, while revenue for the quarter reached $33.43M , beating expectations by +147.03%.
Earnings released on 8 Aug 2024
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $25.12M , beating expectations by +25.64%.
Earnings released on 8 May 2024
EPS came in at $0.17 surpassing the estimated -$0.08 by +312.50%, while revenue for the quarter reached $41.46M , beating expectations by +93.48%.
Earnings released on 11 Mar 2024
EPS came in at $0.01 surpassing the estimated $0.00 by +134.74%, while revenue for the quarter reached $26.61M , beating expectations by +26.46%.
Earnings released on 7 Nov 2023
EPS came in at $0.04 surpassing the estimated -$0.19 by +121.05%, while revenue for the quarter reached $26.38M , beating expectations by +29.27%.
Earnings released on 8 Aug 2023
EPS came in at -$0.02 surpassing the estimated -$0.19 by +89.47%, while revenue for the quarter reached $24.72M , beating expectations by +78.13%.
Earnings released on 9 May 2023
EPS came in at -$0.05 surpassing the estimated -$0.16 by +68.75%, while revenue for the quarter reached $23.50M , beating expectations by +19.95%.
Earnings released on 27 Mar 2023
EPS came in at -$0.42 falling short of the estimated -$0.21 by -100.00%, while revenue for the quarter reached $946.00K , missing expectations by -94.70%.
Earnings released on 8 Nov 2022
EPS came in at -$0.35 falling short of the estimated -$0.32 by -9.37%, while revenue for the quarter reached $16.92M , missing expectations by -6.82%.
Earnings released on 4 Aug 2022
EPS came in at -$0.37 falling short of the estimated -$0.36 by -2.78%, while revenue for the quarter reached $18.17M , beating expectations by +0.28%.
Earnings released on 5 May 2022
EPS came in at -$0.37 falling short of the estimated -$0.35 by -5.71%, while revenue for the quarter reached $17.14M , missing expectations by -19.34%.
Earnings released on 1 Mar 2022
EPS came in at -$0.40 falling short of the estimated -$0.25 by -60.00%, while revenue for the quarter reached $19.73M , beating expectations by +0.78%.
Earnings released on 4 Nov 2021
EPS came in at -$0.35 falling short of the estimated -$0.30 by -16.67%, while revenue for the quarter reached $17.59M , beating expectations by +1.02%.
Earnings released on 5 Aug 2021
EPS came in at -$0.30 falling short of the estimated -$0.26 by -15.38%, while revenue for the quarter reached $16.29M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$0.26 surpassing the estimated -$0.29 by +10.34%, while revenue for the quarter reached $15.97M , missing expectations by -20.45%.
Earnings released on 24 Feb 2021
EPS came in at -$0.31 surpassing the estimated -$0.35 by +11.43%, while revenue for the quarter reached $16.37M , missing expectations by -26.47%.
Earnings released on 5 Nov 2020
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%, while revenue for the quarter reached $17.79M , missing expectations by -33.33%.
CTMX Stock Performance
Access detailed CTMX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.